ArticlePloS one2015
The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Tattoo practices and risk of hepatitis B and hepatitis C infection in the French Constances study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Community Versus Facility-Based Services to Improve the Screening of Active Hepatitis C Virus Infection in Cambodia: The ANRS 12384 CAM-C Cluster Randomized Controlled Trial-Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Article
- Early cost-utility analysis of hepatitis C virus testing for emergency department attendees in France.PLOS global public health · 2023Article
- French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.BMC infectious diseases · 2020Article
- Missed opportunities for diagnosing viral hepatitis C in Poland. Results from routine HCV testing at the Emergency Department in the Hospital for Infectious Diseases in Warsaw.Clinical and experimental hepatology · 2019Article
- HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy.BMC infectious diseases · 2019Article
- Hepatitis C services at harm reduction centres in the European Union: a 28-country survey.Harm reduction journal · 2019Article
- Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016).JMIR research protocols · 2018Article
- A liver health hui: hepatitis C knowledge and associated risk factors in New Zealand gang members and their families.Royal Society open science · 2018Article
- Hepatitis C virus prevention and care for drug injectors: the French approach.Hepatology, medicine and policy · 2018Article
- Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing.Annals of family medicine · 2018Article
- Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.PloS one · 2018Article
- Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015.BMC infectious diseases · 2017Article
- Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017Article
- Article
- Article
- Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy.Reviews in medical virology · 2016Review
- Concordance between self-reported and measured HIV and hepatitis C virus infection status among people who inject drugs in Germany.Hepatology, medicine and policy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent HCV therapeutic advances make effective screening crucial for potential HCV eradication. To identify the target population for a possible population-based screening strategy to complement current risk-based testing in France, we aimed to estimate the number of adults with undiagnosed chronic HCV infection and age and gender distribution at two time points: 2004 and 2014.
methodsA model taking into account mortality, HCV incidence and diagnosis rates was applied to the 2004 national seroprevalence survey.
resultsIn 2014, an estimated 74,102 individuals aged 18 to 80 were undiagnosed for chronic HCV infection (plausible interval: 64,920-83,283) compared with 100,868 [95%CI: 58,534-143,202] in 2004. Men aged 18-59 represented approximately half of the undiagnosed population in 2014. The proportion of undiagnosed individuals in 2004 (43%) varied from 21.9% to 74.1% in the 1945-1965 and 1924-1944 birth cohorts. Consequently, age and gender distributions between the chronically-infected (diagnosed and undiagnosed) and undiagnosed HCV populations were different, the 1945-1965 birth cohort representing 48.9% and 24.7%, respectively.
conclusionsMany individuals were still undiagnosed in 2014 despite a marked reduction with respect to 2004. The present work contributed to the 2014 recommendation of a new French complementary screening strategy, consisting in one-time simultaneous HCV, HBV and HIV testing in men aged 18-60. Further studies are needed to assess the cost-effectiveness and feasibility of such a strategy. We also demonstrated that data on the undiagnosed HCV population are crucial to help adapt testing strategies, as the features of the chronically-infected HCV population are very distinct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.